Global Cell Penetrating Peptide Market, By Type (Protein Derived CPPs, Synthetic CPPs, Chimeric CPPs), By Application (Drug Delivery, Gene Delivery, Diagnostics, Molecular Imaging, Others), By End User (Biopharmaceutical Companies, Contract Research Organization (CROs)/CDMO, Hospitals and Clinics, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : Jan 2024

Code : CMI6553

Pages :179

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Cell Penetrating Peptide Market- Recent Developments

Product Approval and Launch

On August 16, 2023, Revance Therapeutics, Inc., a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved the first therapeutic indication for DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults. DAXXIFY, powered by Peptide Exchange Technology, was previously approved by the U.S. FDA for the temporary improvement of glabellar lines (frown lines) in adults in September 2022 and is the first true innovation in neuromodulator product formulation in more than 30 years.
On January 6, 2023, Revance Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had accepted for review a supplemental biologics license application (sBLA) for DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults, a chronic and debilitating neurologic condition affecting the muscles of the neck.

Business Development Activities by the Market Players

On July 7, 2023, Shanghai Fosun Pharmaceutical (Group) Co., Ltd, a global innovation-driven pharmaceutical and healthcare industry group, announced that the biologics license application (“BLA”) for DAXXIFY (DaxibotulinumtoxinA for injection) for the treatment of cervical dystonia in adults, which was submitted by its holding subsidiary Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. through license-in, had been accepted for review by the National Medical Products Administration (NMPA).
In December 2022, PepGen Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, announced new preclinical data supporting the progression of PGN-EDODM1.
PGN-EDODM1 leverages PepGen’s Enhanced Delivery Oligonucleotide (EDO) technology and consists of the company’s proprietary cell-penetrating peptide conjugated to a steric blocking oligonucleotide cargo. This well-characterized therapeutic oligonucleotide is designed to bind to the CUG repeat expansion hairpin loops in the DMPK transcripts of people with DM1, and thus subsequently correct the downstream transcript mis-splicing events that lead to myotonia and cardiac dysfunction.